Data from pooled safety analysis in patients treated with Palforzia (peanut allergen powder) presented at conference

Data from a pooled analysis of three Phase III and three open-label extension trials of its use in patients aged 4-17 years with peanut allergy for up to 3.5 years shows reported adverse effects were mostly mild, occurred early in treatment and declined over time.

Biospace Inc.